JAGX Latest Press Releases

-- October 21, 2026 --

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder ACCESS Newswire 9:00 AM

-- October 14, 2026 --

Jaguar Health Provides Update Regarding Special Stock Dividend ACCESS Newswire 4:15 PM

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer ACCESS Newswire 9:00 AM

-- October 13, 2026 --

Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock Dividend ACCESS Newswire 9:00 AM

-- October 6, 2026 --

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi ACCESS Newswire 9:05 AM

-- October 2, 2026 --

Jaguar Health Announces a Special Stock Dividend ACCESS Newswire 8:35 PM

-- September 29, 2026 --

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting ACCESS Newswire 4:30 AM

-- September 22, 2026 --

Jaguar Health Receives Fee Waivers from FDA ACCESS Newswire 9:05 AM

-- September 15, 2026 --

Jaguar Health, Inc. Announces Reverse Stock Split ACCESS Newswire 9:00 AM

-- September 10, 2026 --

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF) ACCESS Newswire 9:00 AM

-- September 8, 2026 --

Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs ACCESS Newswire 9:00 AM

-- September 4, 2026 --

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) ACCESS Newswire 8:30 AM

-- August 26, 2026 --

Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs ACCESS Newswire 9:00 AM

-- August 19, 2026 --

Jaguar Health Reports Second Quarter 2026 Financials ACCESS Newswire 4:00 PM

-- August 18, 2026 --

Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates ACCESS Newswire 9:00 AM

-- August 5, 2026 --

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1 ACCESS Newswire 9:00 AM

-- July 28, 2026 --

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog ACCESS Newswire 9:00 AM

-- July 22, 2026 --

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID) ACCESS Newswire 9:00 AM

-- June 30, 2026 --

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) ACCESS Newswire 9:00 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 25, 2026 --

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend ACCESS Newswire 9:00 AM

-- June 23, 2026 --

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs ACCESS Newswire 9:00 AM

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM

-- June 22, 2026 --

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program ACCESS Newswire 9:00 AM

-- June 18, 2026 --

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention ACCESS Newswire 9:00 AM

-- June 12, 2026 --

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases ACCESS Newswire 9:00 AM

-- June 10, 2026 --

Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream Globe Newswire 7:00 AM

-- June 9, 2026 --

Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream Globe Newswire 7:00 AM

-- June 8, 2026 --

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders ACCESS Newswire 4:15 PM